FindTrial
Sign In

S-CUBE

A Randomized, Double-Blind Placebo-Controlled, Comparative Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Failure to Sorafenib monotherapy

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220889
Enrollment
Unknown
Registered
2009-10-02
Start date
2009-10-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

investigational material(s) Generic name etc : S-1 (tegafur + gimeracil + oteracil potassium) INN of investigational material : S-1:tegafur, gimeracil, oteracil potassium Therapeutic category code : 4

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients who are able to do oral administration 2)Patients who have the history of histologically and cytologically confirmed primary hepatocellular carcinoma. 3)Hepatocellular carcinoma patients who are failure to sorafenib monotherapy. 4)Life expectancy of 60 days or more following the start of treatment 5)Patients with written informed consent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Overall Survival—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026